Will Ashworth

Will Ashworth

Expertise: Public and private companies, Portfolio construction

About Will:
Will Ashworth has written about investments full-time since 2008. He loves investing and is passionate about helping others put their money to work. He particularly enjoys creating model portfolios that stand the test of time.

Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He lives in Halifax, Nova Scotia.

You can follow Will on LinkedIn. 

Recent Articles

Several Fintech IPOs Suggest Now Is the Time for SOFI Stock 

Several fintech disruptors look to go public in the days ahead. What, if anything, does that mean for SoFi Technologies and SOFI stock?

Ocugen Neared $16 Yesterday, But I’ll Eat 4 Hats If It Gets to $32

OCGN stock has moved higher despite little evidence anything’s changed regarding Ocugen’s revenue potential in the U.S.

The Key to Victory for Cardano Is Going Where Others Won’t

Cardano is preparing to create a digital identity system for Ethiopia, a country with 110 million people. That's exciting news for investors.

Camber Energy Stock Won’t Get Anywhere Near $10, So Don’t Waste Your Money

A recent article wondered if Camber Energy could reach $10. If buying CEI stock, hoping it could go to double digits. please don't.  

The Future of Dogecoin Is Tied to Its Performance on Robinhood

Dogecoin was just overtaken by its rival, Shiba Inu. Now the competition could continue on Robinhood and further impact the token's price.

Fubo Stock Can Hit $40 This Year

FUBO stock gained almost 25% in October. However, it seems to be having trouble pushing through $30. Is November the time for it to succeed?

Cathie Wood Stands to Make a Lot of Money From Skillz Stock

Portfolio manager Cathie Wood bought 2.1 million shares of SKLZ stock Oct. 21. Ark Invest’s largest ETF now owns more than 13 million shares. 

Cassava Sciences’ Stock Remains an Enigma

Cassava Sciences has lost 26% for the month through Oct. 27. Entering October, SAVA stock looked to go on a big run. It did the opposite.

What Investors Should Remember About Clover Health

There is no question Clover Health remains a risky proposition. However, there is one thing about CLOV stock that could make a difference. 

7 Retail Stocks to Buy Regardless of Supply Shortages

The supply shortages are putting stress on retailers this holiday shopping season. Here are seven retail stocks to buy regardless.